Michael King
Stock Analyst at EF Hutton
(0.79)
# 3,805
Out of 4,883 analysts
117
Total ratings
34.15%
Success rate
-16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $6.56 | +9,808.54% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $4.15 | +28,314.46% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.18 | +245.91% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.65 | +1,839.39% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $6.82 | +904.40% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $7.43 | +2,593.60% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.07 | +675.70% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $547.74 | +57.37% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $44.30 | -45.82% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $5.51 | +2,912.70% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $8.30 | +406.02% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $329.77 | -7.81% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $10.73 | +981.08% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.62 | +293.13% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $35.55 | -32.49% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.90 | +88,907.57% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $23.88 | +92.63% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $35.35 | +171.57% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.69 | +5,094.81% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.38 | +3,068.74% | 1 | Dec 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $7.41 | +318.35% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $545.11 | -93.40% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $6.56
Upside: +9,808.54%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $4.15
Upside: +28,314.46%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.18
Upside: +245.91%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.65
Upside: +1,839.39%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $6.82
Upside: +904.40%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $7.43
Upside: +2,593.60%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.07
Upside: +675.70%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $547.74
Upside: +57.37%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.30
Upside: -45.82%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $5.51
Upside: +2,912.70%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $8.30
Upside: +406.02%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $329.77
Upside: -7.81%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $10.73
Upside: +981.08%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $2.62
Upside: +293.13%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $35.55
Upside: -32.49%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.90
Upside: +88,907.57%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $23.88
Upside: +92.63%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $35.35
Upside: +171.57%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.69
Upside: +5,094.81%
Dec 23, 2021
Initiates: Buy
Price Target: $12
Current: $0.38
Upside: +3,068.74%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $7.41
Upside: +318.35%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $545.11
Upside: -93.40%